

TEKLA LIFE SCIENCES INVESTORS
Form N-Q
August 25, 2017

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL
OMB Number: 3235-0578
Expires: March 31, 2019
Estimated average burden hours per
response.....10.5

FORM N-Q

**QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number 811-06565

Tekla Life Sciences Investors
(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

(Name and address of agent for service)

Registrant's telephone number, including area code: 617-772-8500

Date of fiscal year end: September 30

Date of reporting period: 6/30/17

Item 1. Schedule of Investments.

TEKLA LIFE SCIENCES INVESTORS**SCHEDULE OF INVESTMENTS**

JUNE 30, 2017

(Unaudited)

| SHARES | | VALUE |
|--|--|-------------------|
| CONVERTIBLE PREFERRED AND WARRANTS (a) (b) - 3.3% of Net Assets | | |
| Biotechnology 0.6% | | |
| 1,153,847 | BioClin Therapeutics, Inc. Series A (Restricted) | \$ 750,001 |
| 445,633 | BioClin Therapeutics, Inc. Series B (Restricted) | 333,333 |
| 2,568,939 | EBI Life Sciences, Inc. Series A (Restricted) (c) | 13,102 |
| 933,333 | GenomeDx Biosciences, Inc. Series C (Restricted) | 1,400,000 |
| 90,000 | Trillium Therapeutics, Inc. Series II (d) | 356,400 |
| | | 2,852,836 |
| Health Care Equipment & Supplies (Restricted) 1.9% | | |
| 2,338,198 | AlterG, Inc. Series C | 865,133 |
| 79,330 | CardioKinetix, Inc. Series C | 0 |
| 142,574 | CardioKinetix, Inc. Series D | 0 |
| 439,333 | CardioKinetix, Inc. Series E | 0 |
| 481,378 | CardioKinetix, Inc. Series F | 0 |
| N/A(e) | CardioKinetix, Inc. warrants (expiration 12/11/19) | 0 |
| N/A(e) | CardioKinetix, Inc. warrants (expiration 6/03/20) | 0 |
| 8,822 | CardioKinetix, Inc. warrants (expiration 8/15/24) | 0 |
| 951,000 | IlluminOss Medical, Inc. Series AA | 951,000 |
| 895,848 | IlluminOss Medical, Inc. Junior Preferred | 895,848 |
| 71,324 | IlluminOss Medical, Inc. warrants (expiration 3/31/27) | 0 |
| 3,280,000 | Tibion Corporation Series B | 0 |
| N/A(e) | Tibion Corporation warrants (expiration 07/12/17) | 0 |
| N/A(e) | Tibion Corporation warrants (expiration 10/30/17) | 0 |
| N/A(e) | Tibion Corporation warrants (expiration 11/28/17) | 0 |
| 2,606,033 | Veniti, Inc. Series A (c) | 3,129,324 |
| 1,307,169 | Veniti, Inc. Series B (c) | 1,635,007 |
| 716,720 | Veniti, Inc. Series C (c) | 1,060,459 |
| | | 8,536,771 |
| Life Sciences Tools & Services (Restricted) 0.8% | | |
| 2,446,016 | Labcyte, Inc. Series C | 3,081,980 |
| 107,178 | Labcyte, Inc. Series D | 147,906 |
| 81,480 | Labcyte, Inc. Series E | 131,183 |
| | | 3,361,069 |
| Pharmaceuticals (Restricted) 0.0% | | |
| 2,862,324 | Euthymics Biosciences, Inc. Series A (c) | 2,862 |
| TOTAL CONVERTIBLE PREFERRED AND WARRANTS (Cost \$21,259,353) | | 14,753,538 |

**PRINCIPAL
AMOUNT****CONVERTIBLE AND NON-CONVERTIBLE NOTES - 0.1% of Net Assets**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

Convertible Notes (Restricted)(a) 0.1%

Health Care Equipment & Supplies 0.1%

| | | | |
|----|--------|---|-----|
| \$ | 51,741 | CardioKinetix, Inc. Promissory Note, 5.00%, due 7/31/17 (b) | 410 |
|----|--------|---|-----|

The accompanying notes are an integral part of this Schedule of Investments.

| PRINCIPAL AMOUNT | | VALUE |
|---|---|----------------|
| Health Care Equipment & Supplies continued | | |
| \$ 285,294 | IlluminOss Medical, Inc. Promissory Note, 8.00%, due 3/31/18 | \$ 285,294 |
| | | 285,704 |
| Pharmaceuticals 0.0% | | |
| 26,924 | Euthymics Biosciences, Inc. Promissory Note, 8.00%, due 5/31/18 (b) (c) | 13,462 |
| | | 13,462 |
| | TOTAL CONVERTIBLE NOTES | 299,166 |
| Non-Convertible Notes (Restricted)(a) (b) 0.0% | | |
| Health Care Equipment & Supplies 0.0% | | |
| 238,286 | Tibion Corporation Non-Cvt. Promissory Note, 0.00%, due 12/31/18 (b) | 0 |
| 28,211 | Tibion Corporation Non-Cvt. Promissory Note, 6.00%, due 4/17/18 (b) | 0 |
| | TOTAL NON-CONVERTIBLE NOTES | 0 |
| | TOTAL CONVERTIBLE AND NON-CONVERTIBLE NOTES | |
| | (Cost \$630,828) | 299,166 |

SHARES

| COMMON STOCKS AND WARRANTS 92.0% of Net Assets | | |
|---|---|------------|
| Biotechnology 73.6% | | |
| 396,500 | Adaptimmune Therapeutics plc (b) (f) | 1,780,285 |
| 159,699 | Alexion Pharmaceuticals, Inc. (b) | 19,430,577 |
| 34,026 | Alnylam Pharmaceuticals, Inc. (b) | 2,713,914 |
| 180,082 | Amgen Inc. | 31,015,523 |
| 160,730 | Amicus Therapeutics, Inc. (b) | 1,618,551 |
| 811,227 | ARCA biopharma, Inc. (b) (c) | 1,987,506 |
| 324,491 | ARCA biopharma, Inc. warrants (expiration 6/11/22) (a) (b) (c) | 64,898 |
| 320,135 | Ardelyx, Inc. (b) | 1,632,689 |
| 75,000 | Argenx SE (b) (f) | 1,590,750 |
| 10,000 | AveXis, Inc. (b) | 821,600 |
| 60,000 | Bellicum Pharmaceuticals, Inc. (b) | 700,800 |
| 124,855 | Biogen Inc. (b) | 33,880,653 |
| 148,570 | BioMarin Pharmaceutical Inc. (b) | 13,493,127 |
| 13,273 | bluebird bio, Inc. (b) | 1,394,329 |
| 268,531 | Celgene Corporation (b) | 34,874,121 |
| 40,000 | Collectis S.A. (b) (f) | 1,032,800 |
| 286,472 | Cidara Therapeutics, Inc. (b) | 2,148,540 |
| 45,600 | Clovis Oncology, Inc. (b) | 4,269,528 |
| 159,027 | CytomX Therapeutics, Inc. (b) | 2,464,918 |
| 63,800 | DBV Technologies S.A. (b) (f) | 2,278,298 |
| 114,699 | Dermira, Inc. (b) | 3,342,329 |
| 120,475 | Dynavax Technologies Corporation (b) | 1,162,584 |
| 329 | Eiger BioPharmaceuticals, Inc. warrants (expiration 10/10/18) (a) (b) | 0 |

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

| SHARES | | VALUE |
|---------|---|--------------|
| | Biotechnology continued | |
| 81,000 | Epizyme, Inc. (b) | \$ 1,223,100 |
| 165,599 | Exelixis, Inc. (b) | 4,078,703 |
| 46,000 | Galapagos NV (b) (d) | 3,512,750 |
| 19,000 | Galapagos NV (b) (f) | 1,453,880 |
| 443,120 | Gilead Sciences, Inc. | 31,364,034 |
| 125,000 | Global Blood Therapeutics, Inc. (b) | 3,418,750 |
| 195,822 | Incyte Corporation (b) | 24,655,948 |
| 74,612 | Innoviva, Inc. (b) | 955,034 |
| 28,000 | Intellia Therapeutics, Inc. (b) | 448,000 |
| 256,355 | Karyopharm Therapeutics Inc. (b) | 2,320,013 |
| 142,583 | Merus B.V. (b) | 2,259,941 |
| 152,900 | Momenta Pharmaceuticals, Inc. (b) | 2,584,010 |
| 120,000 | Myovant Sciences Ltd. (b) | 1,404,000 |
| 91,321 | Natera, Inc. (b) | 991,746 |
| 139,631 | Neurocrine Biosciences, Inc. (b) | 6,423,026 |
| 358,000 | Novavax, Inc. (b) | 411,700 |
| 48,761 | Ovid Therapeutics Inc. (b) | 511,503 |
| 111,986 | Ovid Therapeutics Inc. (Restricted) (a)(b) | 1,057,260 |
| 829,191 | Pieris Pharmaceuticals, Inc. (b) | 4,195,706 |
| 23,821 | Pieris Pharmaceuticals, Inc., Series A warrants (expiration 6/8/21) (a) (b) | 57,647 |
| 11,911 | Pieris Pharmaceuticals, Inc., Series B warrants (expiration 6/8/21) (a) (b) | 32,517 |
| 119,945 | Ra Pharmaceuticals, Inc. (b) | 2,247,769 |
| 54,632 | Regeneron Pharmaceuticals, Inc. (b) | 26,831,960 |
| 167,949 | Retrophin, Inc. (b) | 3,256,531 |
| 27,480 | Sage Therapeutics, Inc. (b) | 2,188,507 |
| 68,850 | Sarepta Therapeutics, Inc. (b) | 2,320,933 |
| 67,110 | Seattle Genetics, Inc. (b) | 3,472,271 |
| 24,300 | Spark Therapeutics, Inc. (b) | 1,451,682 |
| 200,000 | Syndax Pharmaceuticals, Inc. (b) | 2,794,000 |
| 150,000 | Trillium Therapeutics Inc. (a)(b)(d) | 594,000 |
| 38,362 | Ultragenyx Pharmaceutical Inc. (b) | 2,382,664 |
| 164,327 | Vertex Pharmaceuticals Incorporated (b) | 21,176,820 |
| 20,000 | Xencor, Inc. (b) | 422,200 |
| 233,331 | Xenon Pharmaceuticals Inc. (b) | 734,993 |
| 13,307 | Zafgen, Inc. (b) | 46,708 |
| | | 326,978,626 |
| | Health Care Equipment & Supplies 2.7% | |
| 495,000 | Alliqua BioMedical, Inc. (b) | 183,150 |
| 130,000 | Cercacor Laboratories, Inc. (Restricted) (a) (b) | 293,040 |
| 93,349 | GenMark Diagnostics, Inc. (b) | 1,104,319 |
| 55,158 | IDEXX Laboratories, Inc. (b) | 8,903,604 |
| 23,012 | Nevro Corp. (b) | 1,712,783 |
| 7,157 | TherOx, Inc. (Restricted) (a) (b) | 143 |
| | | 12,197,039 |

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

| SHARES | | VALUE |
|---|---|-------------|
| Health Care Providers & Services 0.1% | | |
| 148,148 | InnovaCare Health, Inc. (Restricted) (a) (b) (g) | \$ 322,963 |
| Life Sciences Tools & Services 3.9% | | |
| 100,000 | Accelerate Diagnostics, Inc. (b) | 2,735,000 |
| 73,258 | Illumina, Inc. (b) | 12,711,728 |
| 113,500 | NanoString Technologies, Inc. (b) | 1,877,290 |
| | | 17,324,018 |
| Pharmaceuticals 11.7% | | |
| 56,011 | Accelaron Pharma Inc. (b) | 1,702,174 |
| 235,842 | Akorn, Inc. (b) | 7,910,141 |
| 6,363 | Allergan plc | 1,546,782 |
| 232,351 | Auris Medical Holding AG (b) | 166,131 |
| 233,000 | Avadel Pharmaceuticals plc (b) (f) | 2,569,990 |
| 29,100 | Endo International plc (b) | 325,047 |
| 47,865 | Flex Pharma, Inc. (b) | 184,280 |
| 124,140 | Foamix Pharmaceuticals Ltd. (b) (d) | 576,010 |
| 35,949 | Impax Laboratories, Inc. (b) | 578,779 |
| 57,022 | Jazz Pharmaceuticals plc (b) | 8,866,921 |
| 231,280 | Mylan N.V. (b) | 8,978,290 |
| 149,334 | Nabriva Therapeutics plc (b) | 1,677,021 |
| 207,300 | Paratek Pharmaceuticals, Inc. (b) | 4,995,930 |
| 42,015 | Shire plc (f) | 6,943,819 |
| 332,364 | Tetraphase Pharmaceuticals, Inc. (b) | 2,369,755 |
| 115,500 | Verona Pharma plc (b) (f) | 1,348,462 |
| 929,053 | Verona Pharma plc (Restricted) (b) (d) | 1,241,506 |
| 371,622 | Verona Pharma plc, warrants (expiration 4/27/22) (a) (b) (d) | 67,182 |
| | | 52,048,220 |
| TOTAL COMMON STOCKS AND WARRANTS | | |
| (Cost \$279,005,557) | | 408,870,866 |
| EXCHANGE TRADED FUND - 2.1% of Net Assets | | |
| 121,460 | SPDR S&P Biotech ETF | 9,374,283 |
| TOTAL EXCHANGE TRADED FUND | | |
| (Cost \$8,564,136) | | 9,374,283 |
| PRINCIPAL AMOUNT | | |
| SHORT-TERM INVESTMENT - 1.3% of Net Assets | | |
| | Repurchase Agreement, Fixed Income Clearing Corp., repurchase value | |
| | \$5,607,000, 0.12%, dated 6/30/17, due 7/03/17 (collateralized by U.S. Treasury | |
| \$ 5,607,000 | Note 2.125%, due 5/15/25, market value \$5,720,105) | 5,607,000 |
| TOTAL SHORT-TERM INVESTMENTS | | |
| (Cost \$5,607,000) | | 5,607,000 |

The accompanying notes are an integral part of this Schedule of Investments.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

| PRINCIPAL AMOUNT | VALUE |
|---|----------------|
| TOTAL INVESTMENTS BEFORE MILESTONE INTERESTS - 98.8% (Cost \$315,066,774) | \$ 438,904,853 |
| INTEREST | |
| MILESTONE INTERESTS (Restricted)(a) (b) - 1.0% of Net Assets | |
| Pharmaceuticals 1.0% | |
| 1 Afferent Milestone Interest | 1,116,913 |
| 1 Neurovance Milestone Interest | 3,404,477 |
| 1 TargeGen Milestone Interest | 42,375 |
| TOTAL MILESTONE INTERESTS (Cost \$7,503,366) | 4,563,765 |
| TOTAL INVESTMENTS - 99.8% (Cost \$322,570,140) | 443,468,618 |
| OTHER ASSETS IN EXCESS OF LIABILITIES - 0.2% | 944,232 |
| NET ASSETS - 100% | \$ 444,412,850 |

-
- (a) Security fair valued. See Investment Valuation and Fair Value Measurements.
 (b) Non-income producing security.
 (c) Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of \$7,906,620).
 (d) Foreign security.
 (e) Number of warrants to be determined at a future date.
 (f) American Depository Receipt
 (g) Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers.

The accompanying notes are an integral part of this Schedule of Investments.

TEKLA LIFE SCIENCES INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

JUNE 30, 2017

(Unaudited)

Investment Valuation

Shares of publicly traded companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price, as of the close of trading, generally 4 p.m., Eastern time. The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible bonds, corporate and government bonds are valued using a third-party pricing service. Convertible bonds are valued using this pricing service only on days when there is no sale reported. Restricted securities of companies that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction as determined in good faith by Tekla Capital Management LLC (the Adviser) also using fair valuation policies and procedures approved by the Trustees described below. Non-exchange traded warrants of publicly traded companies are generally valued using the Black-Scholes model, which incorporates both observable and unobservable inputs. Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value.

Convertible preferred shares, warrants or convertible note interests in private companies, milestone interests, and other restricted securities, as well as shares of publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.

The Adviser has a Valuation Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value determination is based on a consideration of relevant factors, including both observable and unobservable inputs. Observable and unobservable inputs the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, the company's products or intended markets or the company's technologies; (iii) the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the investments existed, and differences could be material. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of this Schedule of Investments.

Federal Income Tax Cost

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

At June 30, 2017, the cost of securities for Federal income tax purposes was 322,570,194. The net unrealized gain on securities held by the Fund was 120,898,424, including gross unrealized gain of 167,067,321 and gross unrealized loss of 46,168,897.

Other Transactions with Affiliates

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions involving such companies during the period ended June 30, 2017 were as follows:

| Issuer | Value on September 30, 2016 | Purchases | Sales | Income | Value on June 30, 2017 |
|-----------------------------|-----------------------------------|-----------|-------|--------|---------------------------|
| ARCA Biopharma, Inc. | \$ 2,458,019 | | | | \$ 2,052,404 |
| EBI Life Sciences, Inc. | 13,102 | | | | 13,102 |
| Euthymics Biosciences, Inc. | 2,862 | \$ 26,924 | | | 16,324 |
| Veniti, Inc. | 6,174,813 | | | | 5,824,790 |
| | \$ 8,648,796 | \$ 26,924 | \$ | \$ | \$ 7,906,620 |

TEKLA LIFE SCIENCES INVESTORS**NOTES TO SCHEDULE OF INVESTMENTS**

JUNE 30, 2017

(Unaudited)

(continued)

Fair Value Measurements

The Fund uses a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2 includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.). The Independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies that utilize actual market transactions, broker-supplied valuations, and/or other methodologies designed to identify the market value for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

For the period ended June 30, 2017, there was a transfer between Level 2 and 1, Level 1 and 2, Level 3 and 2 and no other transfers between Levels. The amount of transfers between Level 2 and Level 1 was \$1,326,344. The investment was transferred from Level 2 to Level 1 due to a removal of a trading restriction and the value is being supported by quoted prices. The amount of transfers between Level 1 and Level 2 was \$1,926,708. The investment was transferred from Level 1 to Level 2 due to a trading restriction and the value is being supported by significant observable inputs. The amount of transfers between Level 3 and Level 2 was \$2,260,108. The investment was transferred from Level 3 to Level 2 due to a trading restriction and the value is being supported by significant observable inputs. The Fund accounts for transfers between Levels at the beginning of the period.

The following is a summary of the inputs used as of June 30, 2017 to value the Fund's net assets.

| Assets at Value | Level 1 | Level 2 | Level 3 | Total |
|---|----------------|----------------|----------------|--------------|
| Convertible Preferred and Warrants | | | | |
| Biotechnology | | \$ 356,400 | \$ 2,496,436 | \$ 2,852,836 |
| Health Care Equipment & Supplies | | | 8,536,771 | 8,536,771 |
| Life Sciences Tools & Services | | | 3,361,069 | 3,361,069 |
| Pharmaceuticals | | | 2,862 | 2,862 |
| Convertible Notes and Non-Convertible Notes | | | | |
| Health Care Equipment & Supplies | | | 285,704 | 285,704 |
| Pharmaceuticals | | | 13,462 | 13,462 |
| Common Stocks and Warrants | | | | |
| Biotechnology | \$ 325,172,304 | 1,651,260 | 155,062 | 326,978,626 |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

| | | | | |
|----------------------------------|----------------|--------------|---------------|----------------|
| Health Care Equipment & Supplies | 11,903,856 | | 293,183 | 12,197,039 |
| Health Care Providers & Services | | | 322,963 | 322,963 |
| Life Sciences Tools & Services | 17,324,018 | | | 17,324,018 |
| Pharmaceuticals | 50,739,532 | 1,241,506 | 67,182 | 52,048,220 |
| Exchange Traded Fund | 9,374,283 | | | 9,374,283 |
| Short-term Investment | | 5,607,000 | | 5,607,000 |
| Milestone Interest | | | | |
| Pharmaceuticals | | | 4,563,765 | 4,563,765 |
| Other Assets | | | 693,489 | 693,489 |
| Total | \$ 414,513,993 | \$ 8,856,166 | \$ 20,791,948 | \$ 444,162,107 |

TEKLA LIFE SCIENCES INVESTORS**NOTES TO SCHEDULE OF INVESTMENTS**

JUNE 30, 2017

(Unaudited)

(continued)

The following is a reconciliation of level 3 assets for which significant unobservable inputs were used to determine fair value.

| | Balance as of September 30, 2016 | Net realized gain (loss) and change in unrealized appreciation (depreciation) | Cost of purchases and conversions | Proceeds from sales and conversions | Net transfers in (out of) Level 3 | Balance as of June 30, 2017 |
|--|--|--|--|--|--|--------------------------------|
| Level 3 Assets | | | | | | |
| Convertible Preferred and Warrants | | | | | | |
| Biotechnology | \$ 1,845,795 | \$ (785) | \$ 651,426 | | | \$ 2,496,436 |
| Health Care | | | | | | |
| Equipment & Supplies | 11,980,833 | (3,725,653) | 281,790 | \$ (199) | | 8,536,771 |
| Life Sciences Tools & Services | 4,641,917 | (122,159) | 71,671 | (1,230,360) | | 3,361,069 |
| Pharmaceuticals | 2,401,900 | 5,658,195 | 8,708 | (8,065,941) | | 2,862 |
| Convertible and Non-Convertible Notes | | | | | | |
| Health Care | | | | | | |
| Equipment & Supplies | 0 | (36,559) | 337,254 | (14,991) | | 285,704 |
| Pharmaceuticals | 561,304 | 1,111,342 | 32,091 | (1,691,275) | | 13,462 |
| Common Stocks and Warrants | | | | | | |
| Biotechnology | 2,386,782 | 28,057 | 331 | | \$ (2,260,108) | 155,062 |
| Health Care | | | | | | |
| Equipment & Supplies | 214,150 | 79,033 | | | | 293,183 |
| Health Care | | | | | | |
| Providers & Services | 126,667 | 196,296 | | | | 322,963 |
| Pharmaceuticals | 64,304 | 2,084 | 794 | | | 67,182 |
| Milestone Interests | | | | | | |
| Pharmaceuticals | 1,123,203 | 22,762 | 3,417,800 | | | 4,563,765 |
| Other Assets | 374,787 | | 512,084 | (193,382) | | 693,489 |
| Total | \$ 25,721,642 | \$ 3,212,613 | \$ 5,313,949 | \$ (11,196,148) | \$ (2,260,108) | \$ 20,791,948 |
| Net change in unrealized appreciation (depreciation) from investments still held as of June 30, 2017 | | | | | | \$ (464,676) |

The following is a quantitative disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.

Fair Value at June 30, 2017

Valuation Technique

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

| | | | Unobservable Input | Range (Weighted Average) |
|---|------------|---|---|--|
| Private Companies and Other Restricted Securities | 515,284 | Income approach, Black-Scholes | Discount for lack of marketability | 20% - 50% (28.76%) |
| | 14,989,431 | Probability-weighted expected return model | Discount rate Price to sales multiple | 16.60% - 58.51% (25.05%) 1.35 - 12.94 (4.31) |
| | 72,354 | Market approach, recent transaction | (a) | N/A |
| | 5,214,879 | Probability adjusted value | Probability of events Timing of events | 10% - 95% (40.16%) 0.20 - 7.75 (2.53) years |
| \$ | 20,791,948 | | | |

TEKLA LIFE SCIENCES INVESTORS**NOTES TO SCHEDULE OF INVESTMENTS**

JUNE 30, 2017

(Unaudited)

(continued)

(a) The valuation technique used as a basis to approximate fair value of these investments is based upon subsequent financing rounds. There is no quantitative information as these methods of measure are investment specific.

Private Companies and Other Restricted Securities

The Fund may invest in private companies and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represented 5% of the Fund's net assets at June 30, 2017.

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's private companies and other restricted securities at June 30, 2017. The Fund on its own does not have the right to demand that such securities be registered.

| Security (#) | Acquisition Date | Cost | Carrying Value per Unit | Value |
|---|-------------------|--------------|-------------------------|--------------|
| Afferent Milestone Interest | 7/27/16 | \$ 1,123,622 | \$ 1,116,913 | \$ 1,116,913 |
| AlterG, Inc. Series C Cvt. Pfd | 4/12/13 | 1,427,310 | 0.37 | 865,133 |
| BioClin Therapeutics, Inc. | | | | |
| Series A Cvt. Pfd | 1/19/16, 10/24/16 | 750,495 | 0.65 | 750,001 |
| Series B Cvt. Pfd | 3/3/17 | 333,333 | 0.75 | 333,333 |
| CardioKinetix, Inc. | | | | |
| Series C Cvt. Pfd | 5/22/08 | 1,653,409 | 0.00 | 0 |
| Series D Cvt. Pfd | 12/10/10 | 546,109 | 0.00 | 0 |
| Series E Cvt. Pfd | 9/14/11 | 1,254,131 | 0.00 | 0 |
| Series F Cvt. Pfd | 12/04/14 | 1,645,495 | 0.00 | 0 |
| Cvt. Promissory Note | 6/20/17 | 51,741 | 0.79 | 410 |
| Warrants (expiration 12/11/19) | 12/10/09, 2/11/10 | 123 | 0.00 | 0 |
| Warrants (expiration 6/03/20) | 6/03/10, 9/01/10 | 123 | 0.00 | 0 |
| Warrants (expiration 8/15/24) | 8/15/14 | 136 | 0.00 | 0 |
| Cercacor Laboratories, Inc. Common | 3/31/98 | 0 | 2.25 | 293,040 |
| EBI Life Sciences, Inc. Series A Cvt. Pfd | 12/29/11 | 13,597 | 0.01 | 13,102 |
| Euthymics Biosciences, Inc. | | | | |
| Series A Cvt. Pfd | 7/14/10 - 5/21/12 | 2,637,247 | 0.00 | 2,862 |
| Cvt. Promissory Note | 5/22/17 | 26,940 | 50.00 | 13,462 |
| GenomeDx Biosciences, Inc. | | | | |
| Series C Cvt. Pfd | 2/22/16 | 1,401,590 | 1.50 | 1,400,000 |
| IlluminOss Medical, Inc. | | | | |
| Series AA Cvt. Pfd | 1/21/16 | 956,841 | 1.00 | 951,000 |

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-Q

| | | | | |
|--------------------------------|-----------------|---------------|-----------|------------|
| Junior Preferred Cvt. Pfd | 1/21/16 | 1,561,759 | 1.00 | 895,848 |
| Cvt. Promissory Note | 3/28/17 | 285,430 | 100.00 | 285,294 |
| Warrants (expiration 3/31/27) | 3/28/17 | 45 | 0.00 | 0 |
| InnovaCare Health, Inc. Common | 12/21/12 | 643,527 | 2.18 | 322,963 |
| Labcyte, Inc. | | | | |
| Series C Cvt. Pfd | 7/18/05 | 1,284,767 | 1.26 | 3,081,980 |
| Series D Cvt. Pfd | 12/21/12 | 68,643 | 1.38 | 147,906 |
| Series E Cvt. Pfd | 3/27/17 | 70,827 | 1.61 | 131,183 |
| Neurovance Milestone Interest | 3/20/17 | 3,414,295 | 3,404,477 | 3,404,477 |
| Ovid Therapeutics, Inc. Common | 8/7/15 | 1,500,844 | 9.44 | 1,057,260 |
| TargeGen Milestone Interest | 7/20/10 | 2,965,450 | 42,375 | 42,375 |
| TherOx, Inc. Common | 9/11/00, 7/8/05 | 2,388,426 | 0.02 | 143 |
| Tibion Corporation | | | | |
| Series B Cvt. Pfd | 2/23/11 | 905,158 | 0.00 | 0 |
| Non-Cvt. Promissory Note | 7/12/12 | 238,506 | 0.00 | 0 |
| Non-Cvt. Promissory Note | 4/12/13 | 28,211 | 0.00 | 0 |
| Warrants (expiration 07/12/17) | 7/12/12 | 0 | 0.00 | 0 |
| Warrants (expiration 10/30/17) | 10/30/12 | 0 | 0.00 | 0 |
| Warrants (expiration 11/28/17) | 11/28/12 | 0 | 0.00 | 0 |
| Veniti, Inc. | | | | |
| Series A Cvt. Pfd | 2/28/11 | 2,276,891 | 1.20 | 3,129,324 |
| Series B Cvt. Pfd | 5/24/13 | 1,199,887 | 1.25 | 1,635,007 |
| Series C Cvt. Pfd | 12/12/14 | 821,337 | 1.48 | 1,060,459 |
| Verona Pharma plc | | | | |
| Common | 4/27/17 | 1,759,826 | 1.34 | 1,241,506 |
| | | \$ 35,236,071 | \$ | 22,174,981 |

TEKLA LIFE SCIENCES INVESTORS

NOTES TO SCHEDULE OF INVESTMENTS

JUNE 30, 2017

(Unaudited)

(continued)

-
- (#) See Schedule of Investments and corresponding footnotes for more information on each issuer.
Carrying value per unit is greater than \$0.00 but less than \$0.01
Interest received as part of a corporate action for a previously owned security.
-

Item 2. Controls and Procedures.

(a.) The registrant's principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant's disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is (i) accumulated and communicated to the investment company's management, including its certifying officers, to allow timely decisions regarding required disclosure; and (ii) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

(b.) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3. Exhibits.

Separate certifications for each principal executive officer and principal financial officer of the registrant as required by Rule 30a-2(a) under the Act (17 CFR 270.30a-2(a)). Filed herewith.
